Efficacy of the NVX-CoV2373 COVID-19 Vaccine Co-Administered With Seasonal Flu Vaccines
Researchers conducted a study to assess the efficacy of the NVX-CoV2373 COVID-19 vaccine when co-administered with a seasonal influenza vaccine.
Researchers conducted a study to assess the efficacy of the NVX-CoV2373 COVID-19 vaccine when co-administered with a seasonal influenza vaccine.
The randomized, double-blind trial enrolled a total of 1796 participants, of which 1727 completed the study.
Individuals with flu vaccination have lower risks for sepsis, stroke, and DVT, emergency department and ICU admissions.
Study authors analyzed patient data to assess the burden of noninfluenza respiratory virus infection vs influenza in previous seasons.
About one in three individuals with ASCVD did not receive an influenza vaccination in the past year.
Achieving an influenza vaccination rate of at least 80% could be cost-saving.
The National Institutes of Health (NIH) has announced the initiation of a phase 1 clinical trial assessing the safety, tolerability, and efficacy of a “universal” influenza vaccine candidate, H1ssF_3928, in healthy adult patients.
Milder strain of flu has been most common cause of cases this flu season
The current available influenza vaccine may have prevented substantial cases of influenza-associated adverse outcomes.
Influenza-like illness is associated with an increased risk for ischemic stroke and cervical artery dissection.